PDCD1 and colorectal carcinoma: Among the various immunotherapeutic modalities, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have shown remarkable success in several cancer types, including CRC [1,2].